Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 22 05 2018
accepted: 15 10 2018
pubmed: 24 10 2018
medline: 4 9 2020
entrez: 24 10 2018
Statut: ppublish

Résumé

To undertake a systematic review and meta-analysis to determine the influence of tricuspid regurgitation (TR) severity on mortality. We performed a systematic search for studies reporting clinical outcomes of patients with TR. The primary endpoint was all-cause mortality and secondary endpoints were cardiac mortality and hospitalization for heart failure (HF). Overall risk ratios (RR) and 95% confidence intervals (CIs) were derived for each endpoint according to the severity of TR by meta-analysing the effect estimates of eligible studies. Seventy studies totalling 32 601 patients were included in the analysis, with a mean (±SD) follow-up of 3.2 ± 2.1 years. Moderate/severe TR was associated with a two-fold increased mortality risk compared to no/mild TR (RR 1.95, 95% CI 1.75-2.17). Moderate/severe TR remained associated with higher all-cause mortality among 13 studies which adjusted for systolic pulmonary arterial pressures (RR 1.85, 95% CI 1.44-2.39), and 15 studies, which adjusted for right ventricular (RV) dysfunction (RR 1.78, 95% CI 1.49-2.13). Moderate/severe TR was also associated with increased cardiac mortality (RR 2.56, 95% CI 1.84-3.55) and HF hospitalization (RR 1.73, 95% CI 1.14-2.62). Compared to patients with no TR, patients with mild, moderate, and severe TR had a progressively increased risk of all-cause mortality (RR 1.25, 1.61, and 3.44, respectively; P < 0.001 for trend). Moderate/severe TR is associated with an increased mortality risk, which appears to be independent of pulmonary pressures and RV dysfunction.

Identifiants

pubmed: 30351406
pii: 5142409
doi: 10.1093/eurheartj/ehy641
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

476-484

Commentaires et corrections

Type : CommentIn

Auteurs

Nelson Wang (N)

Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Jordan Fulcher (J)

Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.

Nishan Abeysuriya (N)

University of Queensland, Brisbane, Queensland, Australia.

Michele McGrady (M)

Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Ian Wilcox (I)

Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

David Celermajer (D)

Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Sean Lal (S)

Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH